Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20914252 | 0.91 | HSD11B1 (0.38) | MAPTTP53POLBHDAC3CYP2C9 | |
| SCHEMBL20914007 | 0.90 | PLAT (0.43) | MAPTPOLBHDAC3CYP2C9HDAC1 | |
| SCHEMBL20914105 | 0.89 | PLAT (0.42) | MAPTPOLBHDAC3CYP2C9HDAC1 | |
| SCHEMBL20914147 | 0.88 | PLAT (0.38) | MAPTPOLBHDAC3CYP2C9HDAC1 | |
| SCHEMBL20914226 | 0.88 | PLAT (0.47) | PLAT | |
| SCHEMBL20914256 | 0.88 | HDAC3 (0.43) | MAPTTP53POLBHDAC3CYP2C9 | |
| SCHEMBL20931237 | 0.85 | PLAT (0.36) | MAPTPOLBHDAC3CYP2C9HDAC1 | |
| SCHEMBL20913954 | 0.85 | PLAT (0.36) | MAPTPOLBHDAC3CYP2C9HDAC1 | |
| SCHEMBL20914064 | 0.85 | HCRTR1 (0.33) | POLBPLATKMT2A | |
| SCHEMBL20913972 | 0.85 | PLAT (0.42) | POLBPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | MAPT 214/4885TP53 2568/4885POLB 4311/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | MAPT 214/4885TP53 2568/4885POLB 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.